Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review.

ABSTRACT: Prostate cancer (PCa) is the second leading cause of cancer among men, and its diagnosis and adequate staging are fundamental. Among the biomarkers identified in recent years for PCa management, prostate-specific-membrane-antigen (PSMA), physiologically expressed at a low level on healthy prostate and in other normal tissues and highly overexpressed in PCa, represents a reliable marker ideal for imaging and therapy. The development of anti-PSMA antibodies, such as D2B, demonstrated slow clearance of intact antibodies compared with fragments resulting in low tumor-to-blood ratios; however, the modular structural and functional nature of antibodies allowed the generation of smaller fragments, such as scFvs. In this review of the anti-PSMA antibody fragment scFvD2B, we combined further charac

SUBMITTER: Frigerio B 

PROVIDER: S-EPMC8698710 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature